Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2016

View Archived Issues

Apricus expands Vitaros agreement with Ferring, terminates agreement with Sandoz

Prokarium receives funding to develop three new vaccines

Cerecor announces research grant for the development of CERC-501

SRI International patents MAP4K4 inhibitors

Scripps Research Institute discloses agents to treat cancer

PTC provides E.U. and U.S. update on Translarna program

Interim data from REMARC study of Revlimid do not support regulatory filing

Parion Sciences begins phase II study of P-321

Genentech and Constellation Pharmaceuticals develop KAT2B inhibitors

Genentech and Constellation Pharmaceuticals jointly patent KDM2B inhibitors

NantHealth and University of Utah partner on Heritage 1K project

Kite Pharma licenses technology from UCLA

First-in-human data on BACE1 inhibitor LY-3202626

NY-ESO SPEAR T-cell therapy receives orphan drug designation in the E.U.

First patient dosed in phase III study of roxadustat in Japan

Tokai to discontinue ARMOR3-SV study of galeterone based on DMC recommendation

Embera Neurotherapeutics receives grant to continue development of drug for cocaine addition

Amgen and Novartis report first-in-human data on AMG-520

Preclinical and early clinical evaluation of MK-8719

Enigma Biomedical, Biogen and Merck & Co. establish research collaboration

Results from phase Ib trial evaluating second-generation NGF-ECB implants in patients with AD

Hisamitsu reports phase II results for HP-3150 analgesic transdermal patch

Trek Therapeutics gains rights to two HCV drugs from Vertex

NIAID gives grant to Forge Therapeutics to develop drugs for multidrug-resistant bacteria

Viking Therapeutics reports results of study in mice with VK-0214

Merck & Co. returns all rights to SLIT-tablets to ALK-Abello

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.